BRPI0819765A2 - Conjugados de anticorpos anti-rg-1 - Google Patents
Conjugados de anticorpos anti-rg-1Info
- Publication number
- BRPI0819765A2 BRPI0819765A2 BRPI0819765A BRPI0819765A2 BR PI0819765 A2 BRPI0819765 A2 BR PI0819765A2 BR PI0819765 A BRPI0819765 A BR PI0819765A BR PI0819765 A2 BRPI0819765 A2 BR PI0819765A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody conjugates
- conjugates
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99169007P | 2007-11-30 | 2007-11-30 | |
| PCT/US2008/084899 WO2009073524A2 (en) | 2007-11-30 | 2008-11-26 | Conjugates of anti-rg-1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0819765A2 true BRPI0819765A2 (pt) | 2015-05-05 |
Family
ID=40427118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0819765 BRPI0819765A2 (pt) | 2007-11-30 | 2008-11-26 | Conjugados de anticorpos anti-rg-1 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20110020329A1 (pt) |
| EP (1) | EP2211908A2 (pt) |
| JP (1) | JP2011505371A (pt) |
| KR (1) | KR20100101122A (pt) |
| CN (1) | CN101951960A (pt) |
| AR (1) | AR069746A1 (pt) |
| AU (1) | AU2008331507A1 (pt) |
| BR (1) | BRPI0819765A2 (pt) |
| CA (1) | CA2707443A1 (pt) |
| CL (1) | CL2008003525A1 (pt) |
| CO (1) | CO6210734A2 (pt) |
| EA (1) | EA201000921A1 (pt) |
| IL (1) | IL206060A0 (pt) |
| MX (1) | MX2010005683A (pt) |
| NZ (1) | NZ586514A (pt) |
| TW (1) | TW200930407A (pt) |
| WO (1) | WO2009073524A2 (pt) |
| ZA (1) | ZA201003729B (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1769000B1 (en) * | 2004-07-16 | 2014-12-24 | Amgen Research (Munich) GmbH | Expression-enhanced polypeptides |
| EP2344478B1 (en) | 2008-11-03 | 2017-09-27 | Syntarga B.V. | Cc-1065 analogs and their conjugates |
| NO3056203T3 (pt) | 2010-04-21 | 2018-05-12 | ||
| CN103153339B (zh) * | 2010-05-27 | 2021-05-04 | 根马布股份公司 | 针对her2表位的单克隆抗体 |
| CN107253992B (zh) | 2010-05-27 | 2022-03-11 | 根马布股份公司 | 针对her2的单克隆抗体 |
| US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| ES2687225T3 (es) | 2014-01-10 | 2018-10-24 | Synthon Biopharmaceuticals B.V. | Método de purificación de conjugados anticuerpo-fármaco unidos a Cys |
| CA2937561A1 (en) * | 2014-01-29 | 2015-08-06 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof |
| CA3071540A1 (en) * | 2017-07-31 | 2019-02-07 | Tizona Therapeutics | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4978757A (en) * | 1984-02-21 | 1990-12-18 | The Upjohn Company | 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds |
| US4912227A (en) * | 1984-02-21 | 1990-03-27 | The Upjohn Company | 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds |
| US5332837A (en) * | 1986-12-19 | 1994-07-26 | The Upjohn Company | CC-1065 analogs |
| US5084468A (en) * | 1988-08-11 | 1992-01-28 | Kyowa Hakko Kogyo Co., Ltd. | Dc-88a derivatives |
| JP2598116B2 (ja) * | 1988-12-28 | 1997-04-09 | 協和醗酵工業株式会社 | 新規物質ｄｃ１１３ |
| JP2510335B2 (ja) * | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | Ｄｃ―８８ａ誘導体 |
| US5187186A (en) * | 1989-07-03 | 1993-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrroloindole derivatives |
| CA2078118C (en) * | 1990-04-25 | 1999-11-16 | Paul A. Aristoff | Cc-1065 analogs |
| US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| PT705833E (pt) * | 1994-04-22 | 2004-11-30 | Kyowa Hakko Kogyo Kk | Derivado de dc-89 |
| JPH07309761A (ja) * | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | デュオカルマイシン誘導体の安定化法 |
| US5871969A (en) * | 1996-02-12 | 1999-02-16 | Human Genome Sciences, Inc. | Nucleic acids encoding human neuronal attachment factor-1 |
| US6682902B2 (en) * | 1999-12-16 | 2004-01-27 | Schering Aktiengesellschaft | DNA encoding a novel RG1 polypeptide |
| US7087600B2 (en) * | 2001-05-31 | 2006-08-08 | Medarex, Inc. | Peptidyl prodrugs and linkers and stabilizers useful therefor |
| JP2005502703A (ja) * | 2001-09-07 | 2005-01-27 | ザ スクリプス リサーチ インスティテュート | Ｃｃ−１０６５およびデュオカルマイシンのｃｂｉ類似体 |
| US7091186B2 (en) * | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| UY28424A1 (es) * | 2003-07-22 | 2005-02-28 | Schering Ag | Anticuerpos rgi y usos de los mismos. |
| NZ550934A (en) * | 2004-05-19 | 2010-05-28 | Medarex Inc | Chemical linkers and conjugates thereof |
| US7691962B2 (en) * | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
| US7714016B2 (en) * | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| CA2623652C (en) * | 2005-09-26 | 2013-11-26 | Medarex, Inc. | Antibody-drug conjugates and methods of use |
| WO2007059404A2 (en) * | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| JP5189082B2 (ja) * | 2006-05-25 | 2013-04-24 | バイエル・ファルマ・アクチェンゲゼルシャフト | 二量体分子複合体 |
-
2008
- 2008-11-26 CA CA2707443A patent/CA2707443A1/en not_active Abandoned
- 2008-11-26 EA EA201000921A patent/EA201000921A1/ru unknown
- 2008-11-26 WO PCT/US2008/084899 patent/WO2009073524A2/en active Application Filing
- 2008-11-26 JP JP2010536173A patent/JP2011505371A/ja not_active Withdrawn
- 2008-11-26 MX MX2010005683A patent/MX2010005683A/es not_active Application Discontinuation
- 2008-11-26 CN CN2008801259196A patent/CN101951960A/zh active Pending
- 2008-11-26 US US12/745,337 patent/US20110020329A1/en not_active Abandoned
- 2008-11-26 AU AU2008331507A patent/AU2008331507A1/en not_active Abandoned
- 2008-11-26 CL CL2008003525A patent/CL2008003525A1/es unknown
- 2008-11-26 AR ARP080105135A patent/AR069746A1/es not_active Application Discontinuation
- 2008-11-26 BR BRPI0819765 patent/BRPI0819765A2/pt not_active IP Right Cessation
- 2008-11-26 NZ NZ586514A patent/NZ586514A/en not_active IP Right Cessation
- 2008-11-26 TW TW097145816A patent/TW200930407A/zh unknown
- 2008-11-26 EP EP08858236A patent/EP2211908A2/en not_active Withdrawn
- 2008-11-26 KR KR1020107014394A patent/KR20100101122A/ko not_active Application Discontinuation
-
2010
- 2010-05-25 ZA ZA2010/03729A patent/ZA201003729B/en unknown
- 2010-05-28 CO CO10064681A patent/CO6210734A2/es not_active Application Discontinuation
- 2010-05-30 IL IL206060A patent/IL206060A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO6210734A2 (es) | 2010-10-20 |
| EP2211908A2 (en) | 2010-08-04 |
| MX2010005683A (es) | 2010-06-11 |
| TW200930407A (en) | 2009-07-16 |
| KR20100101122A (ko) | 2010-09-16 |
| EA201000921A1 (ru) | 2010-12-30 |
| WO2009073524A3 (en) | 2009-12-10 |
| JP2011505371A (ja) | 2011-02-24 |
| NZ586514A (en) | 2012-05-25 |
| CN101951960A (zh) | 2011-01-19 |
| CA2707443A1 (en) | 2009-06-11 |
| IL206060A0 (en) | 2010-11-30 |
| US20110020329A1 (en) | 2011-01-27 |
| CL2008003525A1 (es) | 2010-01-22 |
| WO2009073524A2 (en) | 2009-06-11 |
| AR069746A1 (es) | 2010-02-17 |
| AU2008331507A1 (en) | 2009-06-11 |
| ZA201003729B (en) | 2011-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2019004I1 (el) | Τροποποιημενα αντισωματα αντι-ιl-23ρ19 | |
| BRPI0814003A2 (pt) | Formulações de anticorpo | |
| BRPI0814252A2 (pt) | Formulações de anticorpo | |
| BRPI0820819A2 (pt) | Formulação de anticorpos | |
| BRPI0907237A2 (pt) | Anticorpo anti-cldn6 | |
| DK1912671T3 (da) | Beta-glucuronid-linker-lægemiddelkonjugater | |
| BRPI0906877A2 (pt) | Anticorpos anti-trkb aperfeiçoados | |
| DK2066695T3 (da) | Anti-myostatin-antistoffer | |
| CR10841A (es) | Imidazotriazinas imidazopirimidinas inhibidores de cinasa | |
| BRPI0922730A2 (pt) | formulação de anticorpo | |
| DK2131860T3 (da) | Anti-sclerostin-antistoffer | |
| BRPI0818380A2 (pt) | Combinação de herbicida-protetor | |
| BRPI0815567A2 (pt) | Anticorpos híbridos antialfa v-integrina projetados | |
| HK1136970A1 (en) | Penta-specific antibody | |
| BRPI0817427A2 (pt) | Anticorpo anti-bst2 | |
| EP2138576A4 (en) | ANTI-CLAUDIN-4 ANTIBODY | |
| BRPI0923047A2 (pt) | "conjugados de proteínas-oligossacarídeos". | |
| BRPI0807991A2 (pt) | Anticorpos anti-il-23r elaborados. | |
| BRPI0814111A2 (pt) | Anticorpo monoclonal citotóxico anticâncer | |
| EP2109625A4 (en) | USE OF ANTIBODY CONJUGATES | |
| DK2132326T3 (da) | Fremgangsmåder | |
| EP2172483A4 (en) | ANTI-MUC17 ANTIBODY | |
| BRPI0819765A2 (pt) | Conjugados de anticorpos anti-rg-1 | |
| BRPI0909633A2 (pt) | anticorpos anti-tyrp1 | |
| FR22C1045I2 (fr) | Conjugués protéine-polymère |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/68 (2017.01), A61P 35/00 (2006.01) |